At ESTRO 37, Elekta Focuses on Millimeter Precision and Personalization of Cancer Care

At ESTRO 37, Elekta Focuses on Millimeter Precision and Personalization of Cancer Care

With new initiatives in 2018, Elekta is poised to transform the delivery of radiation therapy and the oncology data ecosystem for patient-specific care paths

PR Newswire

STOCKHOLM, April 12, 2018

STOCKHOLM, April 12, 2018 /PRNewswire/ --

At the European Society for Radiotherapy and Oncology (ESTRO) 37th Annual Conference, April 20 – 24 in Barcelona, Elekta (EKTA-B.ST) will demonstrate how advances in both radiation and medical oncology are paving the way to deliver more efficient, personalized cancer care and improved patient outcomes.

"Breakthroughs in clinical and scientific cancer research are increasing what we know about cancer. Consequently, Elekta is delivering new precision treatment modalities and digital solutions so that clinicians can better plan, treat and monitor outcomes for each individual patient – and population," said Dr. Richard Hausmann, Elekta's President and CEO. "Innovation has, is and always will be part of Elekta's DNA, as evidenced by two key initiatives: the Elekta MR-linac system, soon to be the first magnetic resonance/radiation therapy (MR/RT) system in the world offering simultaneous high-field imaging and treatment without compromise; and our collaboration with IBM Watson Health to bring artificial intelligence (AI) and machine learning to the field of oncology. At ESTRO 37, we are also celebrating the 50th anniversary of Gamma Knife surgery, demonstrating our commitment to continual advancement and sustainable innovation."

Visitors to Elekta's booth 300 will have the opportunity to participate in interactive demonstrations and learn more about recent Elekta breakthrough technologies, including:

Elekta is also hosting educational meetings and symposia throughout the conference, including:

To learn more about these events, visit: www.elekta.com/ESTRO. For live updates from ESTRO 37, follow @Elekta on Twitter. 

Elekta MR-linac is a work in progress and not available for sale or distribution.

About Elekta
Elekta is proud to be the leading innovator of equipment and software used to improve, prolong and save the lives of people with cancer and brain disorders. Our advanced, effective solutions are created in collaboration with customers, and more than 6,000 hospitals worldwide rely on Elekta technology. Our treatment solutions and oncology informatics portfolios are designed to enhance the delivery of radiation therapy, radiosurgery and brachytherapy, and to drive cost efficiency in clinical workflows. Elekta employs 3,600 people around the world. Headquartered in Stockholm, Sweden, Elekta is listed on NASDAQ Stockholm. www.elekta.com

For further information, please contact:
Oskar Bosson, Global EVP Corporate Communications and Investor Relations
Tel: +46-70-410-7180, e-mail: Oskar.Bosson@elekta.com
Time zone: CET: Central European Time

Michelle Joiner, Director, Global Media Relations
Tel: +1-770-670-2447, e-mail: michelle.joiner@elekta.com
Time zone: ET: Eastern Time

This information was brought to you by Cision http://news.cision.com
http://news.cision.com/elekta/r/at-estro-37--elekta-focuses-on-millimeter-precision-and-personalization-of-cancer-care,c2493698

The following files are available for download:

http://mb.cision.com/Main/35/2493698/820566.pdf

PDF

 

Voltar noticias em Inglês